María Del Mar Tormo Díaz

29PUBLICATIONS
164CO-AUTHORS
Medical infection agents (incl. prions)HaematologyHaematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Transplantation immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Aug 31, 2026
Real-World Outcomes of Midostaurin Plus Intensive Chemotherapy in FLT3-Mutated AML: The PETHRATIFY Study.

|Jun 11, 2026
Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies.

|May 07, 2026
Impact of molecular profiling in patients with acute myeloid leukemia undergoing allogeneic transplantation in first remission: a study by the PETHEMA group.

|Feb 11, 2026
Intensive Chemotherapy With or Without Midostaurin in Adults ≥ 60 Years Old With FLT3-Mutated AML: A FILO-DATAML-PETHEMA Real-World Study.

Gaspar Aspas Requena, Pau Montesinos, Emilie Bérard

|Oct 13, 2025
Quizartinib for Newly Diagnosed FLT3-Internal Tandem Duplication-Negative AML: The Randomized, Double-Blind, Placebo-Controlled, Phase II QUIWI Study.

Pau Montesinos, Rebeca Rodríguez-Veiga, Juan Miguel Bergua

|Sep 01, 2025
Long-term benefits of autologous stem cell transplantation versus intensive chemotherapy consolidation for acute myeloid leukemia patients: A propensity score matching analysis from the PETHEMA AML registry.

Ana Alfonso-Pierola, David Martinez-Cuadrón, Rebeca Rodríguez-Veiga

Pageof 5

Frequent Collaborators

11 joint publications

David Martínez-Cuadrón

9 joint publications

Pau Montesinos

8 joint publications

Teresa Del Bernal Del Castillo

7 joint publications

Lorenzo Algarra-Algarra